No Data
No Data
Novo Nordisk's Wegovy Gets UK Approval as Preventative Treatment for Heart Problems in Obese, Overweight Adults
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Novo Nordisk's (NVO.US) weight-loss drug, Wegovy, has been approved by UK regulatory authorities and can be used to treat heart disease.
Following the United States, the regulatory authority in the United Kingdom has also approved the expansion of the application scope of Novo Nordisk's (NVO.US) weight loss drug Wegovy to treat heart disease.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors
No Data